Eqis Capital Management, Inc. Aerie Pharmaceuticals Inc Transaction History

Eqis Capital Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$11.32 - $16.63 $1.35 Million - $1.98 Million	-119,228 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$15.16 - $18.97 $12,825 - $16,048	846 Added 0.71%	119,228 $1.91 Million
Q1 2021 May 14, 2021	BUY	$13.12 - $20.9 $1.55 Million - $2.47 Million	118,382 New	118,382 $2.12 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.